Key result
Lebetin 2 demonstrates higher binding affinity for human natriuretic peptide receptors than BNP.
Why the study?
Lebetin 2 exerts potent cardioprotection in MI stronger than BNP, but the molecular mechanisms underlying its cardioprotective effect remained to be determined.
In silico modeling demonstrates that the snake venom-derived peptide Lebetin 2 has higher binding affinity and stability for human natriuretic peptide receptors compared to BNP, highlighting its potential as a cardioprotective therapeutic candidate for ischemic heart disease.
Answers are grounded in this paper and cite their sources.
May support Lebetin 2 development for ischemic heart disease; leaves open clinical translation pending human studies.
Lebetin 2 (L2), a natriuretic-like peptide (NP), exerts potent cardioprotection in myocardial infarction (MI), with stronger effects than B-type natriuretic peptide (BNP). To determine the molecular mechanisms underlying its cardioprotection effect, we used molecular modeling, molecular docking and molecular dynamics (MD) simulation to describe the binding mode, key interaction residues as well as mechanistic insights into L2 interaction with NP receptors (NPRs). L2 binding affinity was determined for human, rat, mouse and chicken NPRs, and the stability of receptor-ligand complexes ascertained during 100 ns-long MD simulations. We found that L2 exhibited higher affinity for all human NPRs compared to BNP, with a rank preference for NPR-A > NPR-C > NPR-B. Moreover, L2 affinity for human NPR-A and NPR-C was higher in other species. Both docking and MD studies revealed that the NPR-C-L2 interaction was stronger in all species compared to BNP. Due to its higher affinity to human receptors, L2 could be used as a therapeutic approach in MI patients. Moreover, the stronger interaction of L2 with NPR-C could highlight a new L2 signaling pathway that would explain its additional effects during cardiac ischemia. Thus, L2 is a promising candidate for drug design toward novel compounds with high potency, affinity and stability.
No takes yet. Share an insight, caveat, or question.
Allaoui et al. (2022) studied Myocardial infarction / Ischemic heart disease. Lebetin 2 (L2) vs. B-type natriuretic peptide (BNP) was evaluated on Binding affinity to human NPR-A (kcal/mol) (p=<0.05). Lebetin 2 exhibited significantly higher binding affinity for human natriuretic peptide receptors compared to BNP, including NPR-A (-25.4 vs -18.0 kcal/mol) and NPR-C (-23.4 vs -18.3 kcal/mol).
Synapse has enriched 10 related papers. Consider them for comparative context: